The vaccine Arexvy developed by British pharmaceutical giant GSK protects people against the respiratory syncytial virus (RSV).
The Health Sciences Authority of Singapore (HSA) on May 10 certified the vaccine protects against lower respiratory tract disease caused by the contagious virus, which poses greater risks to older adults.
So far, the vaccine, provided only for Singaporeans aged 60 and above, is available at some general practitioner and specialist clinics at prices of 320-350 SGD (238.5-260.8 USD) per only dose, according to the Straits Times.
According to the HSA, the vaccine is the first for the virus to be available in Singapore, and an application for its use for those between 50 and 59 is still under review./.
VNA